Consun Pharmaceutical Group Limited (HKG:1681)
Hong Kong · Delayed Price · Currency is HKD 14.89
+0.65 (4.56%)
Aug 29, 2025, 4:08 PM HKT
HKG:1681 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2020 |
| 3,267 | 2,967 | 2,590 | 2,340 | 2,045 | 1,753 | Upgrade | |
Revenue Growth (YoY) | 19.29% | 14.56% | 10.71% | 14.43% | 16.65% | 1.42% | Upgrade |
Cost of Revenue | 764.01 | 725.13 | 668.44 | 576.74 | 517.32 | 431.16 | Upgrade |
Gross Profit | 2,503 | 2,242 | 1,922 | 1,763 | 1,527 | 1,322 | Upgrade |
Selling, General & Admin | 1,440 | 1,293 | 1,168 | 1,094 | 900 | 746 | Upgrade |
Other Operating Expenses | -10.61 | -17.55 | -59.45 | -14.47 | -14.8 | -3.82 | Upgrade |
Operating Expenses | 1,430 | 1,267 | 1,096 | 1,048 | 867.15 | 771.54 | Upgrade |
Operating Income | 1,073 | 974.99 | 825.92 | 715.41 | 660.18 | 550.13 | Upgrade |
Interest Expense | -13.98 | -24.89 | -21.26 | -10.93 | -12.91 | -21.4 | Upgrade |
Interest & Investment Income | 87.86 | 88.3 | 68.92 | 52.41 | 39.25 | 27.89 | Upgrade |
Earnings From Equity Investments | -0.83 | -0.07 | - | - | - | - | Upgrade |
Currency Exchange Gain (Loss) | -23.89 | -17.88 | -9.03 | -9.28 | 11.33 | 27.37 | Upgrade |
EBT Excluding Unusual Items | 1,122 | 1,020 | 864.55 | 747.61 | 697.85 | 583.98 | Upgrade |
Gain (Loss) on Sale of Assets | -0.6 | -0.35 | -0.85 | -1.22 | -1.99 | -0.24 | Upgrade |
Pretax Income | 1,121 | 1,020 | 863.7 | 746.39 | 695.86 | 583.74 | Upgrade |
Income Tax Expense | 102.12 | 102.73 | 77.15 | 62.7 | 108.74 | 101.99 | Upgrade |
Earnings From Continuing Operations | 1,019 | 917.37 | 786.55 | 683.7 | 587.12 | 481.74 | Upgrade |
Minority Interest in Earnings | -10.27 | -6.92 | -2.02 | -0.79 | 3.06 | 17.05 | Upgrade |
Net Income | 1,009 | 910.46 | 784.53 | 682.91 | 590.17 | 498.79 | Upgrade |
Net Income to Common | 1,009 | 910.46 | 784.53 | 682.91 | 590.17 | 498.79 | Upgrade |
Net Income Growth | 20.63% | 16.05% | 14.88% | 15.71% | 18.32% | 524.89% | Upgrade |
Shares Outstanding (Basic) | 845 | 821 | 791 | 791 | 802 | 817 | Upgrade |
Shares Outstanding (Diluted) | 855 | 832 | 799 | 792 | 805 | 817 | Upgrade |
Shares Change (YoY) | 6.04% | 4.12% | 0.91% | -1.58% | -1.54% | -4.35% | Upgrade |
EPS (Basic) | 1.19 | 1.11 | 0.99 | 0.86 | 0.74 | 0.61 | Upgrade |
EPS (Diluted) | 1.18 | 1.09 | 0.98 | 0.86 | 0.73 | 0.61 | Upgrade |
EPS Growth | 13.67% | 11.22% | 13.95% | 17.81% | 19.67% | 577.78% | Upgrade |
Free Cash Flow | - | 977.99 | 766.41 | 896.09 | 627.29 | 818.36 | Upgrade |
Free Cash Flow Per Share | - | 1.18 | 0.96 | 1.13 | 0.78 | 1.00 | Upgrade |
Dividend Per Share | 0.586 | 0.564 | 0.408 | 0.265 | 0.244 | 0.236 | Upgrade |
Dividend Growth | 6.73% | 38.03% | 53.92% | 8.58% | 3.66% | 31.87% | Upgrade |
Gross Margin | 76.62% | 75.56% | 74.19% | 75.35% | 74.70% | 75.40% | Upgrade |
Operating Margin | 32.84% | 32.86% | 31.89% | 30.58% | 32.29% | 31.39% | Upgrade |
Profit Margin | 30.88% | 30.68% | 30.29% | 29.19% | 28.86% | 28.46% | Upgrade |
Free Cash Flow Margin | - | 32.96% | 29.59% | 38.30% | 30.68% | 46.69% | Upgrade |
EBITDA | 1,121 | 1,032 | 897.51 | 785.89 | 728.71 | 618.79 | Upgrade |
EBITDA Margin | 34.32% | 34.77% | 34.65% | 33.59% | 35.64% | 35.30% | Upgrade |
D&A For EBITDA | 48.54 | 56.73 | 71.58 | 70.48 | 68.53 | 68.66 | Upgrade |
EBIT | 1,073 | 974.99 | 825.92 | 715.41 | 660.18 | 550.13 | Upgrade |
EBIT Margin | 32.84% | 32.86% | 31.89% | 30.58% | 32.29% | 31.39% | Upgrade |
Effective Tax Rate | 9.11% | 10.07% | 8.93% | 8.40% | 15.63% | 17.47% | Upgrade |
Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.